NO985192D0 - Inklusjonskomplekser av aryl-heterosykliske salter - Google Patents

Inklusjonskomplekser av aryl-heterosykliske salter

Info

Publication number
NO985192D0
NO985192D0 NO985192A NO985192A NO985192D0 NO 985192 D0 NO985192 D0 NO 985192D0 NO 985192 A NO985192 A NO 985192A NO 985192 A NO985192 A NO 985192A NO 985192 D0 NO985192 D0 NO 985192D0
Authority
NO
Norway
Prior art keywords
aryl
inclusion complexes
heterocyclic salts
heterocyclic
salts
Prior art date
Application number
NO985192A
Other languages
English (en)
Other versions
NO985192L (no
NO324373B1 (no
Inventor
Kevin Charles Johnson
Yesook Kim
Ravi Mysore Shanker
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of NO985192L publication Critical patent/NO985192L/no
Publication of NO985192D0 publication Critical patent/NO985192D0/no
Publication of NO324373B1 publication Critical patent/NO324373B1/no

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nanotechnology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Soil Conditioners And Soil-Stabilizing Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Seasonings (AREA)
  • Machine Translation (AREA)
NO19985192A 1996-05-07 1998-11-06 Stoffblanding som omfatter et farmasoytisk akseptabelt salt av en arylpiperazinyl C2- eller C4-alkylenheterocyklus og et cyklodekstrin, samt et salt av ziprasidon NO324373B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1920496P 1996-05-07 1996-05-07
PCT/IB1997/000321 WO1997041896A2 (en) 1996-05-07 1997-04-01 Inclusion complexes of aryl-heterocyclic salts

Publications (3)

Publication Number Publication Date
NO985192L NO985192L (no) 1998-11-06
NO985192D0 true NO985192D0 (no) 1998-11-06
NO324373B1 NO324373B1 (no) 2007-10-01

Family

ID=21791976

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19985192A NO324373B1 (no) 1996-05-07 1998-11-06 Stoffblanding som omfatter et farmasoytisk akseptabelt salt av en arylpiperazinyl C2- eller C4-alkylenheterocyklus og et cyklodekstrin, samt et salt av ziprasidon

Country Status (47)

Country Link
US (2) US6232304B1 (no)
EP (1) EP0900088B1 (no)
JP (1) JP3579060B2 (no)
KR (1) KR20000010823A (no)
CN (1) CN1216923A (no)
AP (1) AP796A (no)
AR (2) AR007002A1 (no)
AT (1) ATE257714T1 (no)
AU (1) AU713711B2 (no)
BG (3) BG64475B2 (no)
BR (1) BR9709213A (no)
CA (1) CA2251912C (no)
CO (1) CO4600677A1 (no)
CZ (1) CZ297847B6 (no)
DE (1) DE69727218T2 (no)
DK (1) DK0900088T3 (no)
DZ (1) DZ2220A1 (no)
EA (1) EA001731B1 (no)
EG (1) EG24135A (no)
ES (1) ES2212809T3 (no)
GE (1) GEP20074185B (no)
GT (1) GT199700044A (no)
HN (1) HN1997000039A (no)
HR (1) HRP970237B1 (no)
HU (1) HU222451B1 (no)
ID (1) ID16866A (no)
IL (1) IL126546A (no)
IS (1) IS2524B (no)
MA (1) MA24172A1 (no)
ME (1) ME00880B (no)
MY (1) MY121999A (no)
NO (1) NO324373B1 (no)
NZ (1) NZ332220A (no)
OA (1) OA10907A (no)
PL (1) PL189324B1 (no)
PT (1) PT900088E (no)
RS (1) RS49532B (no)
SA (1) SA97180024B1 (no)
SI (1) SI0900088T1 (no)
SK (1) SK282032B6 (no)
TN (1) TNSN97075A1 (no)
TR (1) TR199802231T2 (no)
TW (1) TW514529B (no)
UA (1) UA57734C2 (no)
UY (1) UY24544A1 (no)
WO (1) WO1997041896A2 (no)
ZA (1) ZA973874B (no)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA57734C2 (uk) * 1996-05-07 2003-07-15 Пфайзер Інк. Комплекси включення арилгетероциклічних солей
ATE277641T1 (de) * 1996-05-07 2004-10-15 Pfizer Verfahren zur selektion eines salzes zur herstellung eines inklusionskomplexes
IL127497A (en) * 1997-12-18 2002-07-25 Pfizer Prod Inc Medicinal products containing piperazinyl-heterocyclic compounds for the treatment of psychiatric disorders
US6706721B1 (en) 1998-04-29 2004-03-16 Osi Pharmaceuticals, Inc. N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate
US20080113025A1 (en) * 1998-11-02 2008-05-15 Elan Pharma International Limited Compositions comprising nanoparticulate naproxen and controlled release hydrocodone
JP4503724B2 (ja) * 1999-05-10 2010-07-14 栄研化学株式会社 ホタルルシフェリンの安定化方法
UA74803C2 (uk) 1999-11-11 2006-02-15 Осі Фармасьютікалз, Інк. Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
US7087613B2 (en) 1999-11-11 2006-08-08 Osi Pharmaceuticals, Inc. Treating abnormal cell growth with a stable polymorph of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride
US6884885B2 (en) 2000-12-21 2005-04-26 Cerestar Holding B.V. Production of cyclodextrin complexes
US7034013B2 (en) * 2001-03-20 2006-04-25 Cydex, Inc. Formulations containing propofol and a sulfoalkyl ether cyclodextrin
EP1269994A3 (en) * 2001-06-22 2003-02-12 Pfizer Products Inc. Pharmaceutical compositions comprising drug and concentration-enhancing polymers
US20040048876A1 (en) * 2002-02-20 2004-03-11 Pfizer Inc. Ziprasidone composition and synthetic controls
US6869939B2 (en) * 2002-05-04 2005-03-22 Cydex, Inc. Formulations containing amiodarone and sulfoalkyl ether cyclodextrin
RU2342931C2 (ru) * 2002-08-20 2009-01-10 Бристол-Маерс Сквибб Компани Состав на основе комплекса арипипразола
OA12923A (en) * 2002-09-17 2006-10-13 Warner Lambert Co Heterocyclic substituted piperazines for the treatment of schizophrenia.
EP1562546A1 (en) * 2002-10-25 2005-08-17 Pfizer Products Inc. Depot formulations of arylheterocyclic active agents in the form of a suspension
JP2006514923A (ja) * 2002-10-25 2006-05-18 ファイザー・プロダクツ・インク 注射可能な新規なデポ製剤
JP2006506396A (ja) * 2002-10-31 2006-02-23 ファイザー・プロダクツ・インク 固体医薬の液体複合体
CA2499132A1 (en) * 2002-10-31 2004-05-13 Pfizer Products Inc. Solid and semi-solid polymeric ionic conjugates
EP1418492B1 (en) * 2002-11-05 2017-09-20 LG Electronics, Inc. Touch screen mounting assembly for LCD monitor
CN1255105C (zh) * 2002-12-17 2006-05-10 上海医药工业研究院 齐拉西酮及其盐的水溶性包合物及其制备方法
WO2005016325A2 (en) * 2003-06-03 2005-02-24 Teva Pharmaceutical Industries Ltd. CRISTALLINE ZIPRASIDONE HCl AND PROCESSES FOR PREPARATION THEREOF
MXPA06002455A (es) * 2003-09-02 2006-08-31 Pfizer Prod Inc Formas de dosificacion de liberacion sostenida de ziprasidona.
WO2005055952A2 (en) * 2003-12-08 2005-06-23 The Arizona Board Of Regents On Behalf Of The University Of Arizona Synergistic anti-cancer compositions
EP1703898A2 (en) * 2003-12-31 2006-09-27 Alpharma, Inc. Ziprasidone formulations
SI21703A (en) * 2004-01-14 2005-08-31 Lek Farmacevtska Druzba Dd Inclusion complexes of perindopril, procedure of their preparation, pharmaceutical compositions containing these complexes and their application in treatment of hypertensia
WO2005107719A2 (en) * 2004-05-06 2005-11-17 Sandoz Ag Pharmaceutical composition comprising hydrophobic drug having improved solubility
WO2006032957A1 (en) * 2004-05-26 2006-03-30 Pfizer Products Inc. In vitro predictive method
WO2005123086A2 (en) * 2004-06-11 2005-12-29 Dr. Reddy's Laboratories Ltd. Ziprasidone dosage form
BRPI0518187A (pt) * 2004-11-16 2008-11-04 Elan Pharma Int Ltd formulações de olanzapina em nanopartìcula injetáveis
CA2593497A1 (en) * 2005-02-11 2006-08-17 Judith Aronhime Amorphous ziprasidone mesylate
JP2008531721A (ja) * 2005-03-03 2008-08-14 エラン・ファルマ・インターナショナル・リミテッド 複素環式アミド誘導体のナノ粒子状組成物
EP1858891A2 (en) * 2005-03-14 2007-11-28 Teva Pharmaceutical Industries Ltd. Crystalline forms of ziprasidone mesylate
WO2006099452A1 (en) * 2005-03-14 2006-09-21 Teva Pharmaceutical Industries Ltd. Anhydrous ziprasidone mesylate and a process for its preparation
US20070191306A1 (en) * 2005-08-17 2007-08-16 Bristol-Myers Squibb Company FACTOR Xa INHIBITOR FORMULATION AND METHOD
US20100204178A1 (en) 2006-10-02 2010-08-12 James Cloyd Novel parenteral carbamazepine formulation
CN100391458C (zh) * 2006-02-07 2008-06-04 上海医药工业研究院 齐拉西酮或其盐包合物制备方法
CN103288834B (zh) 2006-07-10 2015-07-15 Paion英国有限公司 短效苯并二氮杂*盐及其多晶型
JP2010527925A (ja) * 2007-05-18 2010-08-19 サイドース・エルエルシー ジプラシドン製剤
US8192721B2 (en) * 2007-12-13 2012-06-05 Verrow Pharmaceuticals, Inc. Compositions useful for reducing toxicity associated with gadolinium-based contrast agents
CN101314045B (zh) * 2008-05-09 2013-01-23 沈阳药科大学 桂利嗪的磺丁基醚-β-环糊精包合物及其制剂和制备方法
WO2011148253A2 (en) 2010-05-25 2011-12-01 Aurobindo Pharma Limited Solid dosage forms of antipsychotics
EP2450039A1 (en) 2010-11-08 2012-05-09 PAION UK Ltd. Dosing regimen for sedation with CNS 7056 (Remimazolam)
SI23610A (sl) 2011-01-13 2012-07-31 Diagen@d@o@o Nove adicijske soli ziprasidona postopek za njihovo pripravo in njihova uporaba v terapiji
CN102793701B (zh) * 2011-05-25 2014-12-17 上海医药工业研究院 卢拉西酮组合物
TW201332572A (zh) 2011-12-28 2013-08-16 Otsuka Pharma Co Ltd 具有經取代的β－環糊精之藥物製劑
AR094963A1 (es) 2013-03-04 2015-09-09 Ono Pharmaceutical Co Reacción de oxidación excelente en el índice de conversión
WO2023108156A1 (en) * 2021-12-11 2023-06-15 Beloteca, Inc. Ziprasidone formulations

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3459731A (en) * 1966-12-16 1969-08-05 Corn Products Co Cyclodextrin polyethers and their production
IT1196033B (it) 1984-02-22 1988-11-10 Chiesi Farma Spa Composto ad attivita' antiinfiammatoria ottenuto per complessazione con beta-ciclodestrina e relative formulazioni farmaceutiche
MX173362B (es) 1987-03-02 1994-02-23 Pfizer Compuestos de piperazinil heterociclicos y procedimiento para su preparacion
US4883795A (en) 1988-01-22 1989-11-28 Pfizer Inc. Piperazinyl-heterocyclic compounds
US4831031A (en) * 1988-01-22 1989-05-16 Pfizer Inc. Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
IT1255462B (it) 1992-07-28 1995-11-02 Grazia Maffione Metodo di preparazione di composti di inclusione di nimesulide con ciclodestrine
US5312925A (en) 1992-09-01 1994-05-17 Pfizer Inc. Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride
IT1263831B (it) 1993-01-29 1996-09-04 Paolo Chiesi Complessi di inclusione multicomponente ad elevata solubilita' costituiti da un farmaco di tipo basico, un acido ed una ciclodestrina
HU210922B (en) 1993-05-24 1995-09-28 Europharmaceuticals Sa Nimesulide alkali salt cyclodextrin inclusion complexes their preparation and pharmaceutical compositions containing them
IT1269578B (it) 1994-04-22 1997-04-08 Chiesi Farma Spa Complessi di inclusione multicomponente ad elevata solubilita' costituiti da un farmaco di tipo acido, una ciclodestrina e una base.
BE1008307A3 (fr) 1994-06-16 1996-04-02 Europharmaceuticals Sa Sel de nimesulide hydrosoluble, solution aqueuse le contenant, sa preparation et son utilisation.
TW491847B (en) 1996-05-07 2002-06-21 Pfizer Mesylate dihydrate salts of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2h-indol-2-one
UA57734C2 (uk) * 1996-05-07 2003-07-15 Пфайзер Інк. Комплекси включення арилгетероциклічних солей
SI0904273T1 (en) 1996-05-07 2003-08-31 Pfizer Inc. Mesylate trihydrate salt of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydro-2(1h)-indol-2-one (=ziprasidone), its preparation and its use as dopamine d2 antagonist
ATE277641T1 (de) 1996-05-07 2004-10-15 Pfizer Verfahren zur selektion eines salzes zur herstellung eines inklusionskomplexes
JPH10194996A (ja) * 1996-12-25 1998-07-28 Janssen Pharmaceut Nv アシル化シクロデキストリン含有製薬組成物

Also Published As

Publication number Publication date
IL126546A (en) 2001-01-28
MA24172A1 (fr) 1997-12-31
BG64474B1 (bg) 2005-04-30
AP796A (en) 1999-12-24
NZ332220A (en) 2000-03-27
AR045528A2 (es) 2005-11-02
ID16866A (id) 1997-11-20
RS49532B (sr) 2006-12-15
HN1997000039A (es) 1997-06-26
DK0900088T3 (da) 2004-04-19
HU222451B1 (hu) 2003-07-28
HRP970237A2 (en) 1998-12-31
CA2251912C (en) 2003-06-03
AU713711B2 (en) 1999-12-09
HUP9902799A2 (hu) 1999-12-28
ES2212809T3 (es) 2004-08-01
CZ297847B6 (cs) 2007-04-11
BR9709213A (pt) 1999-08-10
US20010031756A1 (en) 2001-10-18
IS2524B (is) 2009-07-15
DE69727218D1 (de) 2004-02-19
AR007002A1 (es) 1999-10-13
HRP970237B1 (en) 2002-04-30
WO1997041896A3 (en) 1998-01-08
EA199800910A1 (ru) 1999-04-29
JPH11509866A (ja) 1999-08-31
US6399777B2 (en) 2002-06-04
EP0900088B1 (en) 2004-01-14
GEP20074185B (en) 2007-08-10
EP0900088A2 (en) 1999-03-10
US6232304B1 (en) 2001-05-15
YU17297A (sh) 1999-12-27
GT199700044A (es) 1998-10-02
CZ346198A3 (cs) 1999-09-15
BG102894A (en) 1999-09-30
DZ2220A1 (fr) 2002-12-03
WO1997041896A2 (en) 1997-11-13
PL329928A1 (en) 1999-04-26
CN1216923A (zh) 1999-05-19
EG24135A (en) 2008-08-06
HUP9902799A3 (en) 2000-12-28
MY121999A (en) 2006-03-31
BG64475B1 (bg) 2005-04-30
EA001731B1 (ru) 2001-08-27
ME00880B (me) 2006-12-15
SI0900088T1 (en) 2004-04-30
IS4880A (is) 1998-10-27
NO985192L (no) 1998-11-06
OA10907A (en) 2001-10-26
SK282032B6 (sk) 2001-10-08
UA57734C2 (uk) 2003-07-15
SK150498A3 (en) 2000-01-18
TR199802231T2 (xx) 1999-02-22
KR20000010823A (ko) 2000-02-25
ATE257714T1 (de) 2004-01-15
JP3579060B2 (ja) 2004-10-20
DE69727218T2 (de) 2004-11-18
SA97180024B1 (ar) 2005-12-24
AU1937297A (en) 1997-11-26
IL126546A0 (en) 1999-08-17
PT900088E (pt) 2004-04-30
CO4600677A1 (es) 1998-05-08
ZA973874B (en) 1998-11-06
AP9700977A0 (en) 1997-07-31
CA2251912A1 (en) 1997-11-13
UY24544A1 (es) 2000-09-29
TW514529B (en) 2002-12-21
BG64475B2 (bg) 2005-04-30
PL189324B1 (pl) 2005-07-29
NO324373B1 (no) 2007-10-01
TNSN97075A1 (fr) 2005-03-15

Similar Documents

Publication Publication Date Title
NO985192D0 (no) Inklusjonskomplekser av aryl-heterosykliske salter
NO952854D0 (no) 1-arylpyrimidin-derivater
ATE211131T1 (de) Arylsulfonylaminohydroxamsäurederivate
DE59508427D1 (de) 3-aryl-4-hydroxy-delta 3 -dihydrothiophenon-derivate
BR9602637A (pt) Cateter
ATE289994T1 (de) Chinolin-derivate
ATE199150T1 (de) Diphenylmethylenpiperidin-derivate
DE69430587D1 (de) Pyrimidin-acyclonukleosid-derivate
ATA100695A (de) Prothrombin-derivate
EE9600011A (et) Uudsed dialkoksü-püridinüül-bensimidasooli derivaadid
ATE240307T1 (de) Diarylalkenylamin-derivate
DE69527786D1 (de) Diaminomethyliden-derivate
ATE202093T1 (de) 4-amino-benzoylguanidin-derivate
ATE177102T1 (de) Chromanderivate
DE59509209D1 (de) Diphenyloxazolin-derivate
ATE225347T1 (de) Aza-anthracyclinone-derivate
DE69510792D1 (de) Naphtochinonderivate
DE69515498D1 (de) Naphthyridinderivate
ATE202088T1 (de) 4-mercapto-benzoylguanidin-derivate
FI951071A0 (fi) Maetanordning foer maetning av stroemmen i medelspaenningsledningar
ATA45796A (de) Lysin-prolin-derivate
FI946062A0 (fi) Foerfarande foer anvaendning av biomassaoljor i en dieselmotor
FI950355A0 (fi) Foerfarande foer taeckande av soetheten i mjoelkprodukt
FI954003A0 (fi) Styrning av samtal i cellulaert naet
FI1796U1 (fi) Anlaeggning i pappersmaskin/kartongmaskin foer avvattning av en massabana

Legal Events

Date Code Title Description
MK1K Patent expired